APOE and Alzheimer disease: Thus, biological aging may be one biochemical pathway that influences APOE‐ε4 non‐carriers’ risk for AD neuropathologic burden,42 whereas neuropathologic burden is already high in APOE‐ε4 carriers, irrespective, possibly resulting in methylation as a less relevant biochemical pathway to AD pathogenesis in carriers.